Kelly John Alexander 4

What Happened

• Kelly John Alexander, Chief Financial Officer of Precision Biosciences (DTIL), had Restricted Stock Units (RSUs) vest on Jan 20, 2026 that converted into 44,363 shares (3,888 + 13,900 + 26,575). Under a pre-existing Rule 10b5-1 plan, he sold 15,213 of those shares on Jan 21, 2026 at $4.03 per share, generating $61,308. The remaining vested shares (approximately 29,150) were retained by the reporting person after the sell-to-cover tax withholding.

Key Details

• Transaction dates: RSU vesting/conversion on 2026-01-20; open-market sale on 2026-01-21.
• Sale details: 15,213 shares sold at $4.03 each, proceeds $61,308; sale executed pursuant to a 10b5-1 plan (sell-to-cover for taxes).
• RSU issuance: 44,363 shares issued from vesting (3,888; 13,900; 26,575).
• Post-transaction: ~29,150 vested shares remained issued to the insider from this vesting event (44,363 vested minus 15,213 sold), based on this filing.
• Footnotes of note: sales were strictly sell-to-cover for tax/withholding obligations under a 10b5-1 trading plan adopted Jan 17, 2025; RSUs represent contingent rights to one share each; RSU grants originated on 1/20/2023, 4/18/2024, and 8/22/2024 with multi-year vesting schedules.
• Filing timeliness: Reported on 2026-01-22 for a 2026-01-20 vesting — filed within the normal Form 4 reporting window (timely).

Context

• This was RSU vesting and a routine sell-to-cover tax withholding, not a discretionary open-market sell for investment purposes. The derivative entries reflect conversion/settlement of RSUs into common shares (not an options-for-cash purchase). Such sell-to-cover transactions are common following equity awards and do not by themselves imply a change in insider market sentiment.